Unsupervised Hierarchical Clustering of Pancreatic Adenocarcinoma Dataset from TCGA Defines a Mucin Expression Profile that Impacts Overall Survival.
Nicolas JonckheereJulie AuwercxElsa Hadj BachirLucie CordiezNihad BoukroutAudrey VincentBernadette NeveMathieu GautierVíctor Treviño-AlvaradoIsabelle van SeuningenPublished in: Cancers (2020)
Mucins are commonly associated with pancreatic ductal adenocarcinoma (PDAC) that is a deadly disease because of the lack of early diagnosis and efficient therapies. There are 22 mucin genes encoding large O-glycoproteins divided into two major subgroups: membrane-bound and secreted mucins. We investigated mucin expression and their impact on patient survival in the PDAC dataset from The Cancer Genome Atlas (PAAD-TCGA). We observed a statistically significant increased messenger RNA (mRNA) relative level of most of the membrane-bound mucins (MUC1/3A/4/12/13/16/17/20), secreted mucins (MUC5AC/5B), and atypical mucins (MUC14/18) compared to normal pancreas. We show that MUC1/4/5B/14/17/20/21 mRNA levels are associated with poorer survival in the high-expression group compared to the low-expression group. Using unsupervised clustering analysis of mucin gene expression patterns, we identified two major clusters of patients. Cluster #1 harbors a higher expression of MUC15 and atypical MUC14/MUC18, whereas cluster #2 is characterized by a global overexpression of membrane-bound mucins (MUC1/4/16/17/20/21). Cluster #2 is associated with shorter overall survival. The patient stratification appears to be independent of usual clinical features (tumor stage, differentiation grade, lymph node invasion) suggesting that the pattern of membrane-bound mucin expression could be a new prognostic marker for PDAC patients.
Keyphrases
- poor prognosis
- gene expression
- lymph node
- binding protein
- newly diagnosed
- ejection fraction
- prognostic factors
- machine learning
- single cell
- genome wide
- squamous cell carcinoma
- dna methylation
- long non coding rna
- case report
- young adults
- patient reported outcomes
- radiation therapy
- mass spectrometry
- neoadjuvant chemotherapy